[go: up one dir, main page]

MX372905B - Firmas genéticas de trastornos inflamatorios que se relacionan con el hígado. - Google Patents

Firmas genéticas de trastornos inflamatorios que se relacionan con el hígado.

Info

Publication number
MX372905B
MX372905B MX2015004844A MX2015004844A MX372905B MX 372905 B MX372905 B MX 372905B MX 2015004844 A MX2015004844 A MX 2015004844A MX 2015004844 A MX2015004844 A MX 2015004844A MX 372905 B MX372905 B MX 372905B
Authority
MX
Mexico
Prior art keywords
liver
inflammatory disorders
disorders related
gene signatures
genetic signatures
Prior art date
Application number
MX2015004844A
Other languages
English (en)
Other versions
MX2015004844A (es
Inventor
Matthieu Pichaud
Pierre Rimbaud
Stanislav Ehrlich
Original Assignee
Enterome
Agronomique Inst Nat Rech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enterome, Agronomique Inst Nat Rech filed Critical Enterome
Publication of MX2015004844A publication Critical patent/MX2015004844A/es
Publication of MX372905B publication Critical patent/MX372905B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a el área de caracterización de inflamación en relación con la microbiota intestinal, en los trastornos metabólicos y autoinmunes. En particular, se relaciona con la identificación de firmas genéticas que se pueden utilizar como un marcador predictivo de inflamación asociado con las enfermedades, tales como trastornos metabólicos relacionados con el hígado, en particular con la evolución de la esteatosis benigna hacia sus formas más severas (esteatohepatitis y cirrosis) o trastornos autoinmunes, en particular las enfermedades intestinales inflamatorias (Colitis de Crohn y colitis ulcerativa) Por lo tanto estas firmas genéticas se pueden utilizar como un medio de diagnóstico, pronóstico, estratificación para estudios de medicamentos, para el seguimiento del paciente y para la asignación de un tratamiento apropiado.
MX2015004844A 2012-10-17 2013-10-17 Firmas genéticas de trastornos inflamatorios que se relacionan con el hígado. MX372905B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12306286 2012-10-17
PCT/EP2013/071793 WO2014060555A1 (en) 2012-10-17 2013-10-17 Gene signatures of inflammatory disorders that relate to the liver

Publications (2)

Publication Number Publication Date
MX2015004844A MX2015004844A (es) 2015-11-16
MX372905B true MX372905B (es) 2020-04-27

Family

ID=47148686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004844A MX372905B (es) 2012-10-17 2013-10-17 Firmas genéticas de trastornos inflamatorios que se relacionan con el hígado.

Country Status (14)

Country Link
US (2) US10036074B2 (es)
EP (1) EP2909334B1 (es)
JP (2) JP6752016B2 (es)
CN (1) CN104769132B (es)
AU (2) AU2013333882B2 (es)
BR (1) BR112015008621A2 (es)
CA (1) CA2886748A1 (es)
DK (1) DK2909334T3 (es)
ES (1) ES2821383T3 (es)
IL (1) IL238025B (es)
IN (1) IN2015DN03796A (es)
MX (1) MX372905B (es)
NZ (1) NZ707035A (es)
WO (1) WO2014060555A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
EP3423093A4 (en) 2016-03-04 2019-11-13 The Regents of The University of California MICROBIAL CONSORTIUM AND USES THEREOF
AU2017252299A1 (en) * 2016-04-20 2018-12-06 Human Longevity, Inc. Use of a microbiome profile to detect liver disease
CN109152790A (zh) * 2016-05-11 2019-01-04 南加利福尼亚大学 禁食模仿膳食作为胃肠自身免疫性/炎性疾病的免疫调节治疗剂
US11284640B2 (en) 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
EP3606325B1 (en) 2017-04-03 2024-09-04 Gusto Global, LLC Rational design of microbial-based biotherapeutics
CN107271674B (zh) * 2017-06-13 2019-05-07 首都医科大学附属北京地坛医院 一种用于脂肪性肝炎检测的靶标志物gp73及检测应用方法
EP3773645A4 (en) 2018-04-10 2021-11-24 Siolta Therapeutics, Inc. MICROBIAL CONSORTIA
CN108504739A (zh) * 2018-05-15 2018-09-07 浙江大学 一种用于肝癌早期诊断的生物标志物及其应用
WO2020126780A1 (en) * 2018-12-19 2020-06-25 Astrazeneca Ab Biomarker of pnpla3 expression
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
WO2021071864A1 (en) 2019-10-07 2021-04-15 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
CN111884792B (zh) * 2020-06-30 2021-07-09 深圳市永达电子信息股份有限公司 基于忆阻器混沌序列的本征态网络电路信号制备系统和方法
US11688507B2 (en) 2020-12-29 2023-06-27 Kpn Innovations, Llc. Systems and methods for generating a metabolic dysfunction nourishment program
WO2023076740A1 (en) * 2021-11-01 2023-05-04 Colorado State University Research Foundation Non-invasive direct transcriptomic profiling using stool samples for diagnosis of gastrointestinal diseases
WO2023122531A2 (en) * 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Methods of identifying and evaluating liver inflammation and liver fibrosis in a subject by determining a stratified score based on gene expression

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US20020061569A1 (en) * 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
CA2476755C (en) * 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US8119365B2 (en) * 2002-01-23 2012-02-21 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
JPWO2004092365A1 (ja) * 2003-04-13 2006-07-06 株式会社産学連携機構九州 肝障害関連遺伝子群の抽出選択法およびそれを用いた肝障害もしくは肝機能評価・診断方法
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
SI2351772T1 (sl) * 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
FR2893136A1 (fr) * 2005-11-10 2007-05-11 Sanofi Aventis Sa Procedes de diagnostic de maladies hepatiques et de criblage de molecules pour le traitement de ces maladies
WO2011082325A2 (en) * 2009-12-31 2011-07-07 Life Technologies Corporation Sequences of e.coli 055:h7 genome
NZ602704A (en) * 2010-03-01 2015-01-30 Agronomique Inst Nat Rech Method of diagnostic of inflammatory bowel diseases
JP5757032B2 (ja) * 2010-04-05 2015-07-29 学校法人東京医科大学 ｍｉＲＮＡを利用した慢性肝疾患の線維化の検査方法
JP2012125215A (ja) * 2010-12-17 2012-07-05 Osaka City Univ 肝線維症の存在及び／又は肝線維症の重症度の判定方法、判定マーカー、判定用キット、肝線維症の治療の効果予測方法、効果予測マーカー、並びに効果予測用キット
WO2012105590A1 (ja) * 2011-02-01 2012-08-09 アステラス製薬株式会社 非アルコール性脂肪肝炎の鑑別マーカー及び当該マーカーを指標とした非アルコール性脂肪肝炎の診断方法
US20140179726A1 (en) * 2011-05-19 2014-06-26 Virginia Commonwealth University Gut microflora as biomarkers for the prognosis of cirrhosis and brain dysfunction
WO2013036290A1 (en) * 2011-09-09 2013-03-14 Yale University Compositions and methods for assessing and treating inflammatory diseases and disorders
US20140377278A1 (en) * 2012-01-10 2014-12-25 Yale University Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders
CA2888427A1 (en) 2012-10-17 2014-04-24 Institut National De La Recherche Agronomique Prognostic of diet impact on obesity-related co-morbidities
WO2014060538A1 (en) 2012-10-17 2014-04-24 Institut National De La Recherche Agronomique Determination of reduced gut bacterial diversity
EP2909332A1 (en) 2012-10-17 2015-08-26 Institute National de la Recherche Agronomique Determination of a tendency to gain weight
US9459650B2 (en) 2014-03-17 2016-10-04 Qualcomm Incorporated Clock pulse generator for multi-phase signaling

Also Published As

Publication number Publication date
EP2909334A1 (en) 2015-08-26
IN2015DN03796A (es) 2015-10-02
JP2019092522A (ja) 2019-06-20
JP2015535177A (ja) 2015-12-10
US20160068890A1 (en) 2016-03-10
WO2014060555A1 (en) 2014-04-24
US10036074B2 (en) 2018-07-31
IL238025A0 (en) 2015-05-31
ES2821383T3 (es) 2021-04-26
NZ707035A (en) 2018-11-30
MX2015004844A (es) 2015-11-16
BR112015008621A2 (pt) 2018-08-28
JP6752016B2 (ja) 2020-09-09
US20180251819A1 (en) 2018-09-06
IL238025B (en) 2020-05-31
CA2886748A1 (en) 2014-04-24
AU2013333882A1 (en) 2015-05-07
CN104769132B (zh) 2018-05-08
DK2909334T3 (da) 2020-09-28
CN104769132A (zh) 2015-07-08
US10626471B2 (en) 2020-04-21
AU2013333882B2 (en) 2019-05-16
EP2909334B1 (en) 2020-06-24
AU2019210666A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
MX372905B (es) Firmas genéticas de trastornos inflamatorios que se relacionan con el hígado.
UA115540C2 (uk) Антитіло до il-36r
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
NZ602704A (en) Method of diagnostic of inflammatory bowel diseases
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
MX2015015784A (es) Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino.
WO2012047631A3 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
BR112017014107A2 (pt) composição nutricional útil no tratamento de pacientes com ibd
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
EP2895621A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS, FORECAST AND TREATMENT OF NEUROLOGICAL DISEASES
BR112016022055A2 (pt) elementos de ligação ao tnf alfa
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
MX2022010809A (es) Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales.
BR122019026188A8 (pt) Métodos para determinar se um indivíduo tem doença hepática gordurosa não alcoólica (nafld), se um indivíduo com esteatose não alcoólica tem esteato-hepatite não alcoólica e para monitorar um indivíduo com esteatose não alcoólica para o desenvolvimento de nash
EA201170219A1 (ru) Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
NZ738100A (en) Igfbp3 and uses thereof
MX2022008842A (es) Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial.
MA40592A (fr) Compositions et méthodes pour le traitement d'une maladie inflammatoire de l'intestin à l'aide d'une polythérapie à base d'inhibiteurs à petites molécules de récepteur 9 de chimiokine c-c (ccr9) et d'anticorps bloquants anti-intégrine alpha4beta7
BR112017001971A2 (pt) ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais?
IN2014DN06662A (es)
MX2017006959A (es) Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable.
BR112016023450A2 (pt) uso de compostos ctla4 para alcançar remissão livre de fármacos em indivíduos com artrite reumatoide precoce
EA201790642A1 (ru) Аллель-специфическая терапия для гаплотипов болезни хантингтона
EP2687231A4 (en) COMPOSITION FOR THE TREATMENT AND DIAGNOSIS OF PANCREATIC CANCER

Legal Events

Date Code Title Description
FG Grant or registration